Investment analysts at Evercore ISI began coverage on shares of Shire PLC (NASDAQ:SHPG) in a report released on Wednesday, The Fly reports. The firm set an “outperform” rating on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the stock. Stifel Nicolaus lowered their target price on shares of Shire PLC from $250.00 to $245.00 and set a “buy” rating for the company in a report on Friday, June 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $216.00 target price (down previously from $239.00) on shares of Shire PLC in a report on Friday, June 9th. Royal Bank Of Canada set a $221.00 target price on shares of Shire PLC and gave the company a “buy” rating in a report on Thursday, May 18th. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the company a “buy” rating in a report on Saturday, July 1st. Finally, ValuEngine upgraded shares of Shire PLC from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have assigned a buy rating to the company. Shire PLC has a consensus rating of “Buy” and a consensus price target of $222.27.

Shares of Shire PLC (NASDAQ SHPG) traded up 0.49% on Wednesday, hitting $148.44. 1,735,026 shares of the stock were exchanged. Shire PLC has a 1-year low of $147.28 and a 1-year high of $209.22.

Shire PLC (NASDAQ:SHPG) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.53 by $0.20. The company had revenue of $3.75 billion during the quarter. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The business’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.38 EPS. On average, analysts anticipate that Shire PLC will post $14.92 earnings per share for the current year.

WARNING: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/16/shire-plc-shpg-research-coverage-started-at-evercore-isi.html.

A number of institutional investors have recently modified their holdings of SHPG. Howard Hughes Medical Institute raised its position in shares of Shire PLC by 15.5% in the first quarter. Howard Hughes Medical Institute now owns 1,515 shares of the biopharmaceutical company’s stock worth $264,000 after buying an additional 203 shares in the last quarter. Profund Advisors LLC raised its position in Shire PLC by 4.1% in the first quarter. Profund Advisors LLC now owns 4,352 shares of the biopharmaceutical company’s stock worth $758,000 after buying an additional 170 shares during the period. First Manhattan Co. raised its position in Shire PLC by 18.2% in the first quarter. First Manhattan Co. now owns 1,706 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 263 shares during the period. Osborne Partners Capital Management LLC raised its position in Shire PLC by 0.3% in the first quarter. Osborne Partners Capital Management LLC now owns 18,988 shares of the biopharmaceutical company’s stock worth $3,308,000 after buying an additional 60 shares during the period. Finally, Nicolet Bankshares Inc. raised its position in Shire PLC by 25.2% in the first quarter. Nicolet Bankshares Inc. now owns 2,003 shares of the biopharmaceutical company’s stock worth $349,000 after buying an additional 403 shares during the period. Hedge funds and other institutional investors own 20.22% of the company’s stock.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

The Fly

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.